United States Patent 10,849,847: Claim Scope, Amzeeq Patent Landscape, Exclusivity and Generic Entry Risk

U.S. Patent No. 10,849,847 protects a narrow method of treating acne vulgaris with a topical minocycline foam in adolescents aged 15 to 16 years and 11 months. The claims require both a highly specific hydrophobic foam composition and pharmacokinetic results after repeated daily administration. The patent is directed to the Amzeeq-type 4% minocycline foam platform, but it does not broadly cover every topical minocycline product or every acne treatment.

The strongest infringement risk arises when a competing product uses the claimed soybean oil/coconut oil vehicle, the specified foamer complex, a non-silicon-dioxide formulation, and the claimed adolescent plasma exposure profile. The claims are narrower than a conventional composition patent because they require patient age, dosing frequency, treatment duration, formulation architecture and measurable pharmacokinetic outcomes.

What does U.S. Patent 10,849,847 cover?

The patent covers methods, not the foam composition in isolation. Independent claims 1 and 9 each require topical treatment of acne vulgaris with a breakable foam administered once daily for at least seven consecutive days.

The principal claim limitations are:

Limitation	Requirement
Disease	Acne vulgaris
Route	Topical administration
Dosage form	Breakable foam obtained from a foamable composition
Frequency	Once daily
Duration	At least seven consecutive days
Patient age	15 years through 16 years and 11 months
Active ingredient	Minocycline at about 1% to 4% w/w
Vehicle	Hydrophobic vehicle
Hydrophobic solvent	About 70% to 90% by weight of the hydrophobic vehicle
Soybean oil	About 35% to 65% w/w
Coconut oil	About 16.5% to 30.7% w/w
Cyclomethicone	About 3.5% to 6.5% w/w
Light mineral oil	About 1% to 6% w/w
Foamer complex	About 10% to 22% by weight of the hydrophobic vehicle
Propellant	About 3% to 25% w/w
Silicon dioxide	Expressly excluded
PK limitation in claim 1	Plasma minocycline concentration at most 1.9 ng/mL before the seventh day of treatment
PK limitation in claim 9	Plasma AUC of 40.8 ng/mL·hour or less during the 24 hours after administration

The composition limitations are cumulative. A product that contains minocycline in a hydrophobic foam is not within the literal scope unless its ingredients and concentration ranges satisfy the recited limitations.

How narrow are the independent claims?

Claims 1 and 9 are narrow combination claims. Each combines four separate subject areas:

A particular foam platform.
A specific minocycline concentration range.
A defined adolescent population.
A pharmacokinetic result following repeated dosing.

The age limitation materially narrows the claims. A method practiced in adults, patients aged 9 to 14, or patients aged 17 or older would not literally satisfy the express age limitation. The claim also excludes treatment of patients who fall outside the stated age interval, even if they use the same foam.

The formulation limitation is equally important. The claimed composition must include all of the following foamer components within the stated ranges:

Cetostearyl alcohol
Stearic acid
Myristyl alcohol
Hydrogenated castor oil
Beeswax
Stearyl alcohol
Behenyl alcohol

A formulation that replaces one of these ingredients, omits one, or falls outside the stated ranges may avoid literal infringement of claim 1 or claim 9. The separate exclusion of silicon dioxide creates another express design-around feature.

What do claims 2 through 8 add?

Claims 2 through 8 depend from claim 1 and impose narrower pharmacokinetic limitations.

Claim	Added limitation
2	Plasma minocycline concentration of about 1.8 ng/mL three hours after the seventh-day application
3	About 1.8 ng/mL at 12 hours
4	About 1.6 ng/mL at 16 hours
5	About 1.5 ng/mL at 24 hours
6	Maximum measured plasma concentration reached about six hours after daily administration
7	Day-8 plasma concentration is about the same as or less than the pre-seventh-day concentration
8	Plasma concentration is a mean concentration

These claims do not broaden the patent. They create progressively narrower positions based on measured plasma concentrations and timing. Claims 2 through 7 are more vulnerable to disputes over sampling conditions, patient variability, assay methodology, statistical treatment and the meaning of approximate values.

Claim 8 is a measurement-definition claim. It clarifies that the concentration can be a mean concentration, which may allow population-level pharmacokinetic data to satisfy the limitation rather than requiring every individual patient to meet the stated value.

What is the difference between claim 1 and claim 9?

Claim 1 uses a plasma concentration limitation. Claim 9 uses an area-under-the-curve limitation.

Claim 1 requires minocycline to be present in plasma at a concentration of no more than 1.9 ng/mL before application of the seventh day of treatment. Claims 2 through 7 then define specific concentrations or timing characteristics.

Claim 9 requires an AUC of 40.8 ng/mL·hour or less over the 24-hour period following administration. Claim 10 clarifies that the AUC may be a mean area.

The claims therefore create two different infringement pathways:

A concentration-based pathway under claims 1 through 8.
An exposure-based AUC pathway under claims 9 and 10.

A generic applicant could challenge one pathway while remaining exposed to the other. A product with a similar composition but higher systemic exposure could avoid the AUC limitation while potentially satisfying the concentration limitation, depending on the actual pharmacokinetic profile.

What formulation does U.S. Patent 10,849,847 protect?

The patent protects a breakable oil-based foam containing minocycline and a propellant. The hydrophobic vehicle is central to the claim structure.

The claimed solvent system includes soybean oil, coconut oil, cyclomethicone and light mineral oil. The foamer complex contains multiple fatty alcohols, fatty acids, waxes and hydrogenated castor oil. This architecture is consistent with the vehicle used in Amzeeq, the FDA-approved 4% minocycline topical foam for acne vulgaris.[1]

The claims do not cover all oil-based minocycline formulations. They require a particular combination of:

Oil components;
Relative concentration ranges;
Foamer components;
Propellant content;
Absence of silicon dioxide; and
Breakable foam behavior.

The term "breakable foam" is important. A stable or rigid foam may not satisfy the limitation if it does not collapse or break down in the claimed manner. The patent's specification and prosecution history would control the construction of that term in litigation.

Does the patent cover Amzeeq?

The claims are directed to the same general product platform as Amzeeq, a 4% minocycline topical foam. Amzeeq was approved by the FDA in October 2019 for the treatment of moderate-to-severe acne vulgaris in adults and pediatric patients aged nine years and older.[1,2]

The patent claims, however, cover only a narrower age band: 15 years to 16 years and 11 months. FDA approval for a broader population does not itself establish that every approved use falls within the patent claims. The patent is infringed only when the claimed formulation is used in the claimed population and produces the claimed pharmacokinetic result.

The patent can still have commercial value even with the narrow age limitation. A branded sponsor may rely on the patent against a generic product labeled for the broader FDA-approved population if the generic label encourages or directs use in 15- and 16-year-old patients. Induced-infringement analysis would depend on the proposed label, prescribing instructions, promotional materials and the role of the patented use in the product's commercial market.

When does U.S. Patent 10,849,847 lose exclusivity?

The patent's standard term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension.[3]

The patent issued on November 24, 2020. Its expiration date must be taken from the patent face, USPTO Patent Center and any terminal-disclaimer or patent-term-adjustment records. The grant date alone does not determine expiration.

The practical exclusivity date for Amzeeq may be later than the expiration of U.S. Patent 10,849,847 if other Orange Book-listed patents cover the product, its formulation, manufacturing process or method of use. A generic applicant must address each relevant listed patent or wait until the applicable patent and regulatory exclusivity barriers expire.

FDA small-molecule exclusivity is separate from patent protection. Amzeeq's approval was supported by an NDA, not a biologic license application, so biosimilar exclusivity rules do not apply. FDA regulatory exclusivity and patent exclusivity must be analyzed independently.[2,4]

What is the Orange Book status of Amzeeq and this patent?

The FDA Orange Book identifies patents submitted by an NDA holder for approved drug products. A patent may be listed if it claims the drug substance, drug product or an approved method of using the drug.[4]

Patent 10,849,847 should be checked against the current Orange Book listing for Amzeeq, NDA 212510. The relevant commercial question is not only whether the patent exists, but whether it is listed against the NDA and whether the listed claims correspond to the proposed generic's labeling.

For a Paragraph IV challenge, the applicant would need to certify that the listed patent is invalid, unenforceable or will not be infringed. If the NDA holder or patent owner files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to the Hatch-Waxman framework and later court events.[5]

What Paragraph IV challenge risks exist?

The claims present several potential validity and infringement pressure points.

Written description and enablement

The patent claims precise pharmacokinetic values, including 1.8 ng/mL at specified time points and an AUC of 40.8 ng/mL·hour or less. A challenger could argue that the specification does not adequately support the full breadth of the claimed formulation ranges, patient population and PK outcomes.

The strength of that challenge would depend on the number of disclosed formulations, the clinical study design, patient demographics, assay procedures and whether the claimed values were predictable across the full scope.

Obviousness

A challenger could combine prior art relating to:

Topical minocycline;
Oil-based foams;
Acne treatment;
Low systemic exposure;
Foamix vehicle technology; and
Pediatric or adolescent pharmacokinetics.

The patent owner would likely rely on the specific formulation architecture and the reported exposure profile as evidence of nonobviousness. The narrow combination of formulation, age and PK limits may help distinguish the claims from broad prior-art disclosures, but it also creates a factual record that can be attacked through clinical and formulation references.

Indefiniteness

Terms such as "about," "breakable foam," "therapeutically effective amount," "at most," "about the same" and "maximum measured plasma concentration" may create claim-construction disputes. "About" is not automatically indefinite, but its acceptable range depends on the specification and technical context.

Infringement proof

A generic applicant may attempt to avoid infringement by changing:

One or more oils;
The foamer complex;
Propellant concentration;
The use of silicon dioxide;
Minocycline concentration;
Patient age labeling; or
Dosing instructions.

The pharmacokinetic limitations also create proof issues. A method claim cannot be assessed solely from the formulation label if the claimed plasma result is not inherent or expected. Litigation may require clinical studies, population PK modeling or evidence that the claimed exposure necessarily results from the labeled use.

Which companies are challenging the Amzeeq patent estate?

The supplied claim record does not identify a Paragraph IV filer, litigation docket, settlement agreement or licensee. No specific challenger, settlement or court ruling should be attributed to Patent 10,849,847 without a current Orange Book and PACER review.

The likely competitive group includes generic manufacturers developing topical minocycline products, dermatology companies pursuing alternative acne formulations and companies using different foam vehicles. A generic applicant may challenge the patent through an ANDA Paragraph IV certification or avoid it through a formulation and labeling design-around.

What other patents may protect Amzeeq?

The commercial patent estate may include several patent families beyond Patent 10,849,847:

Patent category	Potential protection
Composition patents	Minocycline concentration and oil-based foam vehicle
Formulation patents	Foamer complex, propellant system and foam stability
Method-of-use patents	Acne treatment, dosing frequency and patient subgroup
PK-related patents	Reduced systemic exposure or specified concentration profiles
Manufacturing patents	Preparation, filling, packaging and aerosol production
Device or container patents	Canister, actuator and dispensing system

The existence of related patents does not mean that each is Orange Book-listed or enforceable against an ANDA. Patent family members can have different claim scope, expiration dates and terminal disclaimers.

How strong is the patent estate?

Patent 10,849,847 has moderate commercial strength and narrow literal scope.

Its strengths are:

Multiple required formulation elements;
Explicit exclusion of silicon dioxide;
Defined patient population;
Repeated-dose pharmacokinetic limitations;
Separate concentration and AUC claim groups; and
Potential relevance to an FDA-approved product platform.

Its weaknesses are:

The age limitation excludes much of the acne population;
The formulation ranges may permit practical design-arounds;
PK limitations can generate measurement and reproducibility disputes;
"About" ranges and foam terminology may require claim construction; and
The patent does not independently establish broad protection for all minocycline foams.

The patent is stronger as a blocking patent against a closely copied Amzeeq formulation than as a platform patent against competing topical minocycline products.

What generic launch scenarios exist?

At-risk launch before patent expiration

A generic applicant could launch before final resolution of Paragraph IV litigation. That approach exposes the applicant to damages and a possible injunction. The risk is highest if the generic formulation closely matches the claimed vehicle and the label includes adolescent use.

Label carve-out

A generic could remove or narrow the patented adolescent use from its labeling if FDA permits the proposed carve-out. This strategy may reduce direct method-of-use infringement risk but may not eliminate liability if the product is marketed or routinely prescribed for the patented use.

Formulation design-around

The most direct strategy is to alter the vehicle. Replacing one claimed oil, changing the foamer complex or using silicon dioxide may avoid literal infringement. The applicant must assess the doctrine of equivalents, because a minor substitution may still be challenged as an equivalent formulation.

Delayed launch

A company may wait until the relevant patent estate expires or secure a settlement with a defined launch date. The value of that option depends on the remaining Orange Book patents, regulatory exclusivity and the commercial size of the adolescent acne market.

How does Patent 10,849,847 compare with broad formulation patents?

A broad composition patent generally focuses on the product itself and can cover manufacture, sale and use without proving a particular patient age or PK result. Patent 10,849,847 is different. It requires performance of a treatment method in a defined adolescent group.

That structure may make the patent harder to assert against an unapproved or differently labeled product. It can also make the patent harder to invalidate if the claimed combination was not suggested by the prior art. The resulting litigation profile depends heavily on the FDA label and the actual clinical use of the generic product.

Is there biosimilar risk?

There is no biosimilar pathway for Amzeeq because minocycline is a small-molecule drug. The relevant competitive pathway is an ANDA for a generic topical product, not a biosimilar application under the Public Health Service Act.

The principal barriers are formulation equivalence, bioequivalence requirements, patent certifications, labeling strategy and manufacturing comparability. FDA approval of a generic minocycline foam would not automatically resolve patent infringement exposure.

Key Takeaways

Patent 10,849,847 claims treatment of acne vulgaris with a specific minocycline breakable foam.
The claims require once-daily administration for at least seven days.
The protected population is limited to patients aged 15 through 16 years and 11 months.
The formulation must contain defined ranges of soybean oil, coconut oil, cyclomethicone, light mineral oil, seven foamer components, minocycline and propellant.
Silicon dioxide is expressly excluded.
Claims 1 through 8 rely primarily on plasma concentration and timing limitations.
Claims 9 and 10 rely on a 24-hour AUC limitation.
The patent is commercially relevant to the Amzeeq product platform but does not broadly cover every topical minocycline formulation.
The strongest design-around opportunities involve vehicle composition, foamer selection, propellant content, labeling and patient population.
Generic risk depends on the complete Orange Book patent estate, not Patent 10,849,847 alone.
Amzeeq faces generic Hatch-Waxman risk rather than biosimilar risk.

FAQs

Does Patent 10,849,847 cover minocycline foam for patients under age 15?

No. The supplied claims require a subject between 15 years and 16 years and 11 months old. Treatment of younger patients does not literally satisfy that limitation.

Can a generic avoid Patent 10,849,847 by using a different oil?

Potentially. A materially different oil system may avoid literal infringement, but the complete formulation must be compared against every limitation and assessed under the doctrine of equivalents.

Does the patent cover oral minocycline?

No. The claims require topical administration of a breakable foam. Oral capsules, tablets and other systemic dosage forms fall outside the claimed method.

Is the 1.9 ng/mL plasma limit measured after the seventh dose?

Claim 1 requires the concentration to be at most 1.9 ng/mL before applying the seventh day of treatment. Dependent claims then specify concentrations at selected times after the seventh-day application.

Can a product containing silicon dioxide infringe the patent?

A product containing silicon dioxide would not literally satisfy the express limitation that the foamable composition does not comprise silicon dioxide. Equivalence and claim-construction issues could still arise in litigation.

References

U.S. Food and Drug Administration. (2019). Amzeeq (minocycline) topical foam, 4%: Prescribing information. NDA 212510.
U.S. Food and Drug Administration. (2019, October 18). FDA approves new treatment for acne. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-acne
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	AMZEEQ	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	212379-001	Oct 18, 2019		RX	Yes	Yes	10,849,847	⤷ Start Trial				TREATMENT OF NON-NODULAR ACNE VULGARIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2978573	⤷ Start Trial
Mexico	2017011630	⤷ Start Trial
Mexico	2020012139	⤷ Start Trial
Mexico	377365	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,849,847

Which drugs does patent 10,849,847 protect, and when does it expire?

Summary for Patent: 10,849,847